PURPOSE: The purpose of the study was to determine if a diagnosis of ovarian cancer is independently associated with an increased risk of Clostridium difficile infection (CDI). METHODS: The University HealthSystem Consortium database was queried to perform a retrospective cohort study of women with and without ovarian cancer who were diagnosed with CDI. Inpatients undergoing total hysterectomy from 2008 to 2012 were studied. Ovarian cancer patients were compared to non-ovarian cancer patients to evaluate relative risk (RR) of CDI. Adjustment was made for known or suspected CDI risk factors to determine RR of CDI independent of these variables. RESULTS: In this study, 115,203 patients were included. CDI was reported in 0.80 % of ovarian cancer patients and in 0.31 % of non-ovarian cancer patients (RR = 2.50; 95 % confidence interval (CI) = 2.02 to 3.35). Stratification by age, presence of other comorbidities, or administration of antineoplastic drugs did not significantly modify the elevated risk associated with ovarian cancer. Significantly increased risk in ovarian cancer patients was no longer observed after controlling for broad-spectrum antibiotic administration (RR = 1.28, 95 % CI = 0.39 to 4.13). Compared to non-ovarian cancer patients, ovarian cancer patients were more frequently treated with broad-spectrum antibiotics, had a 39 % longer mean duration of therapy, and had 2.5-fold greater mean total exposure to broad-spectrum antibiotics. CONCLUSIONS: After adjustment for antibiotic use, ovarian cancer patients are not at excess risk of CDI. Additional studies are needed to understand the patterns of broad-spectrum antibiotic prescription for ovarian cancer patients leading to increased exposure. If feasible, reduction of this exposure may decrease morbidity in this population.
PURPOSE: The purpose of the study was to determine if a diagnosis of ovarian cancer is independently associated with an increased risk of Clostridium difficileinfection (CDI). METHODS: The University HealthSystem Consortium database was queried to perform a retrospective cohort study of women with and without ovarian cancer who were diagnosed with CDI. Inpatients undergoing total hysterectomy from 2008 to 2012 were studied. Ovarian cancerpatients were compared to non-ovarian cancerpatients to evaluate relative risk (RR) of CDI. Adjustment was made for known or suspected CDI risk factors to determine RR of CDI independent of these variables. RESULTS: In this study, 115,203 patients were included. CDI was reported in 0.80 % of ovarian cancerpatients and in 0.31 % of non-ovarian cancerpatients (RR = 2.50; 95 % confidence interval (CI) = 2.02 to 3.35). Stratification by age, presence of other comorbidities, or administration of antineoplastic drugs did not significantly modify the elevated risk associated with ovarian cancer. Significantly increased risk in ovarian cancerpatients was no longer observed after controlling for broad-spectrum antibiotic administration (RR = 1.28, 95 % CI = 0.39 to 4.13). Compared to non-ovarian cancerpatients, ovarian cancerpatients were more frequently treated with broad-spectrum antibiotics, had a 39 % longer mean duration of therapy, and had 2.5-fold greater mean total exposure to broad-spectrum antibiotics. CONCLUSIONS: After adjustment for antibiotic use, ovarian cancerpatients are not at excess risk of CDI. Additional studies are needed to understand the patterns of broad-spectrum antibiotic prescription for ovarian cancerpatients leading to increased exposure. If feasible, reduction of this exposure may decrease morbidity in this population.
Authors: Mamoon A Aldeyab; Mary P Kearney; Michael G Scott; Motasem A Aldiab; Yaser M Alahmadi; Feras W Darwish Elhajji; Fidelma A Magee; James C McElnay Journal: J Antimicrob Chemother Date: 2012-08-16 Impact factor: 5.790
Authors: J Wiström; S R Norrby; E B Myhre; S Eriksson; G Granström; L Lagergren; G Englund; C E Nord; B Svenungsson Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790
Authors: William N Southern; Rabin Rahmani; Olga Aroniadis; Igal Khorshidi; Andy Thanjan; Christopher Ibrahim; Lawrence J Brandt Journal: Surgery Date: 2010-02-08 Impact factor: 3.982
Authors: Marc Zerey; B Lauren Paton; Amy E Lincourt; Keith S Gersin; Kent W Kercher; B Todd Heniford Journal: Surg Infect (Larchmt) Date: 2007-12 Impact factor: 2.150
Authors: Erik R Dubberke; Kimberly A Reske; Yan Yan; Margaret A Olsen; L Clifford McDonald; Victoria J Fraser Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: Alla Aroutcheva; Julie Auclair; Martin Frappier; Mathieu Millette; Karen Lolans; Danielle de Montigny; Serge Carrière; Stephen Sokalski; William E Trick; Robert A Weinstein Journal: Probiotics Antimicrob Proteins Date: 2016-03 Impact factor: 4.609
Authors: Andrew I T Hebbard; Monica A Slavin; Caroline Reed; Jason A Trubiano; Benjamin W Teh; Gabrielle M Haeusler; Karin A Thursky; Leon J Worth Journal: Support Care Cancer Date: 2017-02-02 Impact factor: 3.603
Authors: James L Alexander; Ian D Wilson; Julian Teare; Julian R Marchesi; Jeremy K Nicholson; James M Kinross Journal: Nat Rev Gastroenterol Hepatol Date: 2017-03-08 Impact factor: 46.802
Authors: Analia Rodríguez Garzotto; Antonio Mérida García; Nerea Muñoz Unceta; M Mar Galera Lopez; M Ángeles Orellana-Miguel; C Vanesa Díaz-García; Susana Cortijo-Cascajares; Hernán Cortes-Funes; M Teresa Agulló-Ortuño Journal: Support Care Cancer Date: 2014-11-20 Impact factor: 3.603